Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EACD 2020: How the use of functional assessments in clinical trials provides meaningful information for physicians treating children with cerebral palsy

11/25/2020 | 03:41am EST

By Andreas Lysandropoulos MD, PhD, Vice President Head Global Medical Affairs Neuroscience at Ipsen

An estimated 17 million people worldwide are affected by cerebral palsy (CP).1 One of the most common forms of the condition is spastic CP, which affects approximately 80% of patients.1-2

While there is no cure for CP, the associated spasticity can be managed well with a combination of physical therapies and medications. Even minor adjustments to treatment management can deliver significant improvements in quality of life for these patients. This is why I'm so pleased that the Ipsen Neuroscience team is sharing new research at the annual European Academy of Childhood of Childhood Disability (EACD) scientific meetings, taking place between 25-28 November.

The ability to successfully evaluate the impact that treatments can have for people with CP is critical in continuing to advance the science and improve treatment and quality of life for these patients. At present, most clinical trials in this area rely on the Modified Ashworth Scale (MAS) which works by measuring the resistance of a muscle to passive stretching. However, new data shared at EACD utilizes Assisting Hand Assessment (AHA) to measure how effectively a child uses their affected hand in conjunction with their well-functioning hand, a cutting-edge outcome measure in this area.

In CP patients with one-sided impairments (hemiparesis), AHA provides a new perspective on hand function evaluation by measuring how well the affected hand is used in conjunction with the well-functioning hand. For the young people affected by CP, children who want to play and explore the world around them, the ability to use their hands is key.3 AHA uses a play session with specific toy kits for children and adolescents, encouraging the spontaneous use of both hands, to enable researchers to evaluate hand function in a natural environment; not assessing what children can do, but what they actually do when faced with a more spontaneous, real-life problem requiring them to use their hands. Measuring the efficacy of therapies in this way is directly linked to how children with CP live - evaluating the real impact on their day-to-day lives, and enabling physicians to guide treatment planning and evaluate treatment effects.

Evaluating cutting-edge outcome measures such as AHA is another example of how Ipsen puts patients at the center of everything we do, right down to designing our clinical trials - delivering on our commitment to patient centricity even in challenging pediatric conditions. This research, and studies like it, will help to create and support solutions that meet the real needs of patients and help to improve their lives.

References

  1. Cerebral Palsy Foundation. Key Facts. Available at: yourcpf.org/statistics. Accessed November 2020.
  2. Cook Children's. Cerebral Palsy. Available at: https://cookchildrens.org/neurology/conditions/Pages/cerebral-palsy.aspx. Accessed November 2020.
  3. Krumlinde-Sundholm L, Holmefur M, Kottorp A, Eliasson AC. The Assisting Hand Assessment: current evidence of validity, reliability, and responsiveness to change. Dev Med Child Neurol. 2007 Apr;49(4):259-64. doi: 10.1111/j.1469-8749.2007.00259.x. PMID: 17376135.

Disclaimer

Ipsen SA published this content on 25 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2020 08:40:05 UTC


© Publicnow 2020
All news about IPSEN
01/21IPSEN : appoints Gwenan White as Executive Vice President Communications and Pub..
AQ
01/20IPSEN : Appoints Gwenan White as Executive Vice President, Communications and Pu..
BU
01/19IPSEN : Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF
BU
01/18IPSEN : TOXINS 2021, new analyses of pivotal Phase III trial data highlight long..
AQ
01/15IPSEN : Dysport Offers Long Response Duration At Approved Dose
MT
01/15TOXINS 2021 : New analyses of pivotal Phase III trial data highlight long durati..
BU
01/14IPSEN : Why 2021 is the year for R&D progress
PU
01/04MARKET CHATTER : Ipsen's China Arm Forms Strategic Partnership with Kang Long Gr..
MT
2020IPSEN : Monthly statement on outstanding equity shares and voting rights
CO
2020IPSEN : and the fight against corruption
PU
More news
Financials
Sales 2020 2 637 M 3 200 M 3 200 M
Net income 2020 461 M 559 M 559 M
Net Debt 2020 747 M 906 M 906 M
P/E ratio 2020 13,4x
Yield 2020 1,44%
Capitalization 5 947 M 7 240 M 7 216 M
EV / Sales 2020 2,54x
EV / Sales 2021 2,27x
Nbr of Employees 5 807
Free-Float 42,0%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 89,66 €
Last Close Price 72,00 €
Spread / Highest target 56,9%
Spread / Average Target 24,5%
Spread / Lowest Target 4,17%
EPS Revisions
Managers and Directors
NameTitle
David G. Loew Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN6.04%7 240
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159